Nikolaev I.S. 1, Shamtieva K.V.2, Pugachev A.Y.3, Melnichenko V.Y.1, Fedorenko D.A.1
1 Pirogov National Medical and Surgical Center, Moscow
2 Scientific center of neurology, Moscow
3 «Family» Clinic, Moscow
Background of the study: for more than 20 years, high-dose immunosuppressive therapy (HIST) with autologous hematopoietic stem cell transplantation (autoHSCT) has been successfully used in the world to stop the progression of multiple sclerosis (MS). The effectiveness of this therapy has been proven in many multicenter randomized trials. However, data on the outcomes of such treatment in the early post-transplant period (up to three months) in the world literature is not enough.
Objective: to evaluate the early neurological outcomes of HIST followed by autoHSCT in patients with relapsing-remitting multiple sclerosis (RRMS).
Methods: the study included 20 patients with significant RMS (McDonald 2017). Among them, 6 men and 14 women aged 19 to 51 years (median 34.2±9.6 years) who underwent VIST (R-Cph 200) followed by autoHSCT. The follow-up period ranged from 31 to 34 days (median 31.45 days). At both points of the study, the neurological status was assessed according to the Scripps neurologic rating scale (SNRS), the score on the extended Kurtzke disability scale (EDSS), MRI of the brain and spinal cord with contrast, the presence of spasticity in the paretic limbs according to the modified Ashworth scale (MAS).
Results. After treatment, significant differences were obtained for both EDSS (p = 0.0001) and SNRS (p=0.00004). Improvement on the EDSS scale averaged 0.5 points [0; 1] in 13 patients (65%). According to the SNRS scale — 5 points [3; 9] in 19 patients (95%). The disappearance of contrast accumulation was noted in three patients (30%), however, in one (10%), an accumulation of a contrast agent was detected, which was not previously observed. The presence of negative dynamics according to the EDSS and SNRS scales was not observed in this patient. In 6 (75%) patients, a decrease in the severity of the increase in pyramidal tone according to MAS was revealed by at least 1 point.
Conclusion. HIST with autoHSCT can improve the performance of the neurological rating scale and the extended disability scale even in the early post-transplant period. For a more accurate assessment of the effectiveness of treatment, it is preferable to evaluate the dynamics on the SNRS scale due to its complexity and completeness of the indicators used. Absence of accumulation of a contrast agent during MRI in the early stages after treatment was detected in 30% of cases. In 75% of patients, a decrease in spasticity by 1 point on the MAS scale was noted 2 weeks after VIST with autoHSCT.
Keywords: relapsing-remitting multiple sclerosis, HIST+autoHSCT, autologous hematopoietic stem cell transplantation. Autologous hematopoietic stem cell transplantation, HSCT.
1. Gusev EI, Hecht AB. Clinical guidelines for multiple sclerosis, 2018. (In Russ.)
2. Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014; 122: 231.
3. Gusev EI. Rassejannyj skleroz i drugie demielinizirujushhie zabolevanija. M.: Miklosh, 2004. Р.162. (In Russ.)
4. Votintseva MV, Petrov AM, Stolyarov ID. Monoclonal antibodies: present and future in the treatment of multiple sclerosis (based on the materials of the 32nd Congress of the European Committee for the Treatment and Research of Multiple Sclerosis-ECTRIMS). Annaly klinicheskoj i eksperimental’noj nevrologii. 2017; 11(2). (In Russ.) doi 10.18454/ACEN.2017.2.12. — EDN YZFQLX.
5. Kotov SV, Yakushina TI, Lizhdvoi VYu. Long-term comparative study of the effectiveness of drugs that change the course of multiple sclerosis. Almanac of clinical medicine. 2011; 25. (In Russ.)
6. Fassas A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone marrow transplantation. 1997; 20(8): 631-638.
7. Novik AA, Bogdanov AN. Principles of bone marrow and peripheral blood stem cell transplantation. St. Petersburg: VMA, 2001. (In Russ.)
8. Shevchenko YL, Novik AA, Kuznetsov AN, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis. Cellular Therapy and Transplantation. doi 10.1007/s00277-015-2337-8.
9. Atkins HL, Bowman M, Allan D, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016; 388: 576-85.
10. Burt RK, Balabanov R, Burman J, et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019; 321(2): 165-174. doi:10.1001/jama.2018.18743.
11. Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015; 84: 981-8.
12. Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2015; 313: 275-84.
13. Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology 2017; 88: 842-52.
14. Koziol JA, et al. Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial. Canadian journal of neurological sciences. 1999; 26(4): 283-289.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33: 1444-1452.
16. Paty DW, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1988; 38(2): 180.
17. Offenbacher H. et al. Assessment of MRI criteria for a diagnosis of MS. Neurology. 1993; 43(5): 905.
18. Barnes MP, et al. Spasticity in multiple sclerosis. Neurorehabilitation and neural repair. 2003; 17(1): 66-70.
19. Fedorenko DA. Principy ocenki jeffektivnosti autologichnoj transplantacii gemopojeticheskih stvolovyh kletok u pacientov s limfomami i rassejannym sklerozom [dissertation], 2015. (In Russ.)
20. Nguyen LT, et al. Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: an open label uncontrolled clinical trial. BMC pediatrics. 2017; 17(1): 104.